Stay updated with breaking news from Embark Laboratories. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A groundbreaking paper in Nature describes a promising new therapy for obesity that leads to greater weight loss in mice than existing medications. The approach smuggles molecules into the brain's appetite centre and affects the brain's neuroplasticity.
In addition to Eli Lilly, Novo Nordisk and Moderna, Regeneron also produced its latest quarterly earnings report Thursday morning.
Novo Nordisk is buying ocedurenone, an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA).
Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.
The BioInnovation Institute welcomes eight new companies to its Venture Lab program